Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/17694
Title: Correlation between molecular analysis, diagnosis according to the 2015 WHO classification of unresected lung tumours and TTF1 expression in small biopsies and cytology specimens from 344 non-small cell lung carcinoma patients.
Authors: Russell, Prudence A;Rogers, Toni-Maree;Solomon, Benjamin;Alam, Naveed;Barnett, Stephen A;Rathi, Vivek;Williams, Richard A;Wright, Gavin M;Conron, Matthew
Affiliation: Department of Anatomical Pathology, St Vincent's Hospital, University of Melbourne, Fitzroy, Australia
Department of Pathology, Peter MacCallum Cancer Centre, East Melbourne, Australia
Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, University of Melbourne, East Melbourne, Australia
Department of Surgery, St Vincent's Hospital, University of Melbourne, Fitzroy, Australia
Department of Surgery, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Department of Respiratory and Sleep Medicine, St Vincent's Hospital, University of Melbourne, Fitzroy, Vic, Australia
Issue Date: Oct-2017
EDate: 2017-08-12
Citation: Pathology 2017; 49(6): 604-610
Abstract: We investigated correlations between diagnosis according to the 2015 World Health Organization (WHO) classification of unresected lung tumours, molecular analysis and TTF1 expression in small biopsy and cytology specimens from 344 non-small cell lung carcinoma (NSCLC) patients. One case failed testing for EGFR, KRAS and ALK abnormalities and six had insufficient tumour for ALK testing. Overall mutation rate in 343 cases was 48% for the genes tested, with 19% EGFR, 33% KRAS and 4% BRAF mutations, and 5% ALK rearrangements detected. More EGFR-mutant (78%) and ALK-rearranged (75%) tumours had morphologic adenocarcinoma than KRAS-mutant (56%) tumours. Despite no significant difference in the overall rate of any molecular abnormality between morphologic adenocarcinoma (52%) and NSCLC, favour adenocarcinoma (47%) (p = 0.18), KRAS mutations were detected more frequently in the latter group. No significant difference in the overall rate of any molecular abnormality between TTF1 positive (49%) and TTF1 negative tumours (44%) (p = 0.92) was detected, but more EGFR-mutant (97%) and ALK-rearranged tumours (92%) were TTF1 positive than KRAS-mutant tumours (68%). Rates of EGFR, KRAS and BRAF mutations and ALK rearrangements in this Australian NSCLC patient population are consistent with the published international literature. Our findings suggest that 2015 WHO classification of unresected tumours may assist in identifying molecular subsets of advanced NSCLC.
URI: http://ahro.austin.org.au/austinjspui/handle/1/17694
DOI: 10.1016/j.pathol.2017.07.002
PubMed URL: 28811082
Type: Journal Article
Subjects: 2015 WHO classification
EGFR mutation
Non-small cell lung carcinoma
TTF1 immunohistochemistry
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.